MethylGene
MethylGene is a clinical-stage biopharmaceutical company, founded in 1997 and headquartered in Montréal, Canada, focused on developing and commercializing novel cancer therapeutics.
- Company typePrivate
- Founded1997
- HeadquartersMontréal, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What MethylGene does
MethylGene is described in firmographic source material as a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer therapeutics. Founded in 1997 and headquartered in Montréal, Canada, the company operated with a small team of 11–50 employees. Across four disclosed financing events between 1999 and 2012, MethylGene raised approximately $71.8 million from a mix of Canadian development and institutional investors (Fonds de solidarité FTQ, BDC Venture Capital, Société Innovatech du Grand Montréal, Sofinov, Canadian Medical Discoveries Fund, RBC Capital, GeneChem) and US biotech-specialist funds (Baker Brothers Advisors, OrbiMed, Tang Capital Management, Tavistock Life Sciences, ProQuest Investments, QVT Financial, Tan Capital Partners). The 2011 and 2012 rounds (~$34.5M and ~$26.1M respectively) were led by or included participation from dedicated healthcare investors, indicating sustained institutional conviction in the cancer therapeutics pipeline through that period.
No commercial products, pricing models, customer logos, distribution channels, or revenue figures are disclosed in the source data, consistent with a pre-commercial clinical-stage biotech whose economics are driven by R&D burn funded through equity capital. The data set also presents an internal conflict: while firmographic and funding history consistently describe MethylGene as a Montréal-based oncology biopharmaceutical company, the current methylgene.com website publishes Vietnamese-language content on relationships and sexuality topics under the brand "Gene Love – Khoa Học & Tình Yêu," with copyright @2025 and article dates extending through 2026. This suggests the original biotech entity is not actively reflected on the present-day domain; the analysis above is grounded in the firmographic, funding, and leadership record of the historical MethylGene.
MethylGene firmographics
Firmographics- Name
- MethylGene
- Legal name
- MethylGene
- Website
- https://methylgene.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MethylGene is a clinical-stage biopharmaceutical company, founded in 1997 and headquartered in Montréal, Canada, focused on developing and commercializing novel cancer therapeutics.
- Ownership category
- akta.pro rank
MethylGene industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where MethylGene is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Markets served
MethylGene business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
MethylGene product offering
Product offeringCore offering
MethylGene is a clinical-stage biopharmaceutical company that develops and aims to commercialize novel cancer therapeutics. The company's work centers on pharmaceutical research and development of oncology drug candidates intended for eventual clinical use and commercialization.
Differentiator
Problem solved
Functional benefit
Companies that use MethylGene
Customer profileIdeal customer profiles1 record
MethylGene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
MethylGene partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
MethylGene competitors and assessment
Company assessmentDirect peers
- Loxo Oncology: Precision-medicine oncology drug developer working on highly selective kinase inhibitors. Comparable in development stage and targeting modality to MethylGene's clinical-stage assets.
- Exelixis: Clinical-stage developer of small-molecule kinase inhibitors for oncology (cabozantinib). Operates at similar scale and modality to MethylGene's historical pipeline of targeted kinase candidates.
- Epizyme: Clinical-stage developer of epigenetic and small-molecule oncology therapeutics. Closely aligned with MethylGene's epigenetic-targeting orientation (e.g., MGCD0103, an HDAC inhibitor) before Ipsen acquisition.
- Onyx Pharmaceuticals: Clinical-stage oncology developer of small-molecule kinase-targeted therapies, historically comparable in pipeline focus and clinical-stage profile before its acquisition by Amgen.
- Blueprint Medicines: Clinical- and commercial-stage precision oncology company developing small-molecule kinase and other targeted therapies, with similar headcount and clinical-stage trajectory.
- ARIAD Pharmaceuticals: Clinical-stage small-molecule oncology company focused on kinase inhibition (ponatinib), historically a near-perfect modal match for MethylGene's MGCD kinase portfolio before its acquisition by Takeda.
- Pharmacyclics: Clinical-stage targeted oncology developer of hematology and solid-tumor therapies with a similar headcount and clinical-stage profile to MethylGene, now part of AbbVie.
- Array BioPharma: Clinical-stage small-molecule oncology developer with a pipeline of kinase inhibitors, comparable to MethylGene's modality and stage profile before its acquisition by Pfizer.
- Mirati Therapeutics: Clinical-stage targeted oncology company developing small-molecule kinase inhibitors, historically comparable in scale and pipeline depth to MethylGene before its acquisition by Bristol Myers Squibb.
- Curis: Clinical-stage targeted oncology and precision-medicine company at comparable scale, focused on small-molecule and biologic candidates against validated oncology targets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
MethylGene social profiles
Digital presenceMethylGene financial estimates
Financial estimateRevenue estimate
Valuation estimate
MethylGene leadership team
Management profileNumber of profiles
Profiles1 record
MethylGene funding detail
Funding detailFunding overview
Funding rounds4 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MethylGene M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MethylGene
What does MethylGene do?
MethylGene is a clinical-stage biopharmaceutical company that develops and aims to commercialize novel cancer therapeutics. The company's work centers on pharmaceutical research and development of oncology drug candidates intended for eventual clinical use and commercialization.
Is MethylGene a public or private company?
MethylGene is a private company. It is classified as venture growth investor backed and is currently operating.
When was MethylGene founded?
MethylGene was founded in 1997. It employs 11 to 50 people.
Where is MethylGene based?
MethylGene is headquartered in Montréal, Canada, in the North America region.
Who are MethylGene's main competitors?
Direct peers on record are Loxo Oncology, Exelixis, Epizyme, Onyx Pharmaceuticals, Blueprint Medicines, ARIAD Pharmaceuticals, Pharmacyclics, Array BioPharma, Mirati Therapeutics and Curis.
Does MethylGene have an API?
No public API is recorded for MethylGene.
What industry is MethylGene in?
MethylGene's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.